When to add Weight-Loss pills? new study tests timing for teens
NCT ID NCT04007393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 150 teens aged 12-17 with severe obesity to find the best time to add a weight-loss pill (phentermine) if lifestyle changes alone weren't enough. Participants first tried lifestyle therapy for 12 or 24 weeks, then those who didn't lose enough weight started the medication. The goal was to see how much their body mass index (BMI) changed over 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Phentermine
What this could lead to
If successful, this could show doctors the best way to combine lifestyle changes with medication to help teens with severe obesity lose weight more effectively.
What could go wrong
This is a small, early-phase study (Phase 2) with only 150 teens. The results may not apply to all teens, and phentermine can have side effects like increased heart rate or insomnia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENT OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55414, United States